Safety of apixaban in Indian patients undergoing elective total knee replacement or total hip replacement surgery: A multi-center, phase-IV study

Himanshu Panchal; Abhijit Agashe; Parag K Sancheti; Namrata B Kulkarni; Santosh R Taur

doi:10.1177/20503121211049962

Safety of apixaban in Indian patients undergoing elective total knee replacement or total hip replacement surgery: A multi-center, phase-IV study

SAGE Open Med. 2021 Oct 7:9:20503121211049962. doi: 10.1177/20503121211049962. eCollection 2021.

Authors

Himanshu Panchal¹, Abhijit Agashe², Parag K Sancheti³, Namrata B Kulkarni⁴, Santosh R Taur⁴

Affiliations

¹ Civil Hospital, B. J. Medical College, Ahmedabad, India.
² Sahyadri Specialty Hospital, Pune, India.
³ Sancheti Institute for Orthopedics and Rehabilitation, Pune, India.
⁴ Pfizer Ltd., Mumbai, India.

Abstract

Background: Venous thromboembolism is a significant source of morbidity and mortality following total hip replacement and total knee replacement. Apixaban has been proven to be efficacious without increased risk of bleeding in phase-III trials in patients undergoing total knee replacement and total hip replacement. Due to paucity of data on safety of apixaban in Indian patients, this phase-IV study was conducted to evaluate safety of apixaban in patients undergoing total knee replacement and total hip replacement.

Methods: In this non-comparative phase-IV clinical trial, patients undergoing elective total knee replacement or total hip replacement surgery, or a revision of at least one component of total knee replacement or total hip replacement, were enrolled. The eligible patients were given the approved dosage of apixaban 12 to 24 h after completing the skin wound closure. The primary safety outcome was the composite of the International Society on Thrombosis and Haemostasis-defined major bleeding and clinically relevant non-major bleeding events at the end of the treatment. The secondary efficacy endpoint was the composite of venous thromboembolism/all-cause death at the end of the treatment.

Results: A total of 498 patients received apixaban prophylaxis therapy. Six (1.2%) bleeding adverse events were observed during the treatment period. Only one bleeding event was adjudicated as an International Society on Thrombosis and Haemostasis-defined clinically relevant non-major bleeding event (moderate severity). There were no fatal bleeding events and no deaths following the treatment. One venous thromboembolism event, that is, symptomatic distal left leg DVT, was reported in a total knee replacement patient and was adjudicated during the treatment period.

Conclusion: Apixaban demonstrated a favorable safety profile for venous thromboembolism prevention in Indian patients undergoing total knee replacement or total hip replacement.

Keywords: Total knee replacement; anticoagulant; thromboembolism; total hip replacement; venous.